Display options
Cite
Tkacz J, Ingham MP, Brady BL, et al. Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis. Am Health Drug Benefits. 2015;8(9):494-505
Tkacz, J., Ingham, M. P., Brady, B. L., Meyer, R., & Ruetsch, C. (2015). Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis. American health & drug benefits, 8(9), 494-505.
Tkacz, Joseph, et al. "Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis." American health & drug benefits vol. 8,9 (2015): 494-505.
Tkacz J, Ingham MP, Brady BL, Meyer R, Ruetsch C. Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis. Am Health Drug Benefits. 2015 Dec;8(9):494-505. PMID: 26834936; PMCID: PMC4719139.
Copy Download .nbib Format: NLM
Share it on

Am Health Drug Benefits. 2015 Dec;8(9):494-505.

Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis.

American health & drug benefits

Joseph Tkacz, Michael P Ingham, Brenna L Brady, Roxanne Meyer, Charles Ruetsch

Affiliations

  1. Mr Tkacz is Director of Analytics, Health Analytics, Columbia, MD.
  2. Mr Ingham is Director, HECOR, Janssen Scientific Affairs, Horsham, PA.
  3. Dr Brady is Project Director, Health Analytics, Columbia, MD.
  4. Dr Meyer is Manager, HECOR, Janssen Scientific Affairs, Horsham, PA.
  5. Dr Ruetsch is President and Chief Executive Officer, Health Analytics, Columbia, MD.

PMID: 26834936 PMCID: PMC4719139

Abstract

BACKGROUND: Published studies on adherence to biologic medications show that many types of calculation methods are used. However, infused biologics are not well-suited to typical measures of adherence, such as proportion of days covered.

OBJECTIVE: To construct and assess 7 novel adherence measures potentially applicable to infusible biologic agents and compare outcomes for 2 infusible biologics used for the treatment of patients with rheumatoid arthritis (RA).

METHODS: Adults (aged ≥18 years) diagnosed with RA (ie, 2 or more 714.x claims) who received ≥24 months of continuous medical and pharmacy eligibility and who started taking abatacept or infliximab therapy were selected from a large commercial insurer database of medical and pharmacy claims. The 7 new adherence measures included cumulative amount of time with a refill gap ≥20% (CG20) beyond the expected infusion interval, cumulative time off treatment, days of uninterrupted use (DoUU), observed versus expected refill ratio (OvERR), repeated observations of underuse (RoUU), variance in time between infusions, and time to discontinuation (TTD). Mean observed infusion intervals were calculated and served as a reference measure of adherence.

RESULTS: The mean maintenance intervals approximated recommended guidelines. The mean observed infusion interval for abatacept recipients was 33 days (recommended, 28 days); it was 53 days (recommended, 56 days) for patients receiving infliximab. Three measures demonstrated a significant positive relationship to the mean observed infusion interval-CG20 (r = .258), DoUU (r = .212), and TTD (r = .081; P <.05). OvERR (r = -.072) and RoUU (r = -.189; P <.05) showed significant negative correlations. Real-world comparisons showed that adherence was significantly (P <.001) greater for the infliximab group according to most measures.

CONCLUSION: New measures of adherence correlate significantly with mean maintenance intervals. Future studies should examine relationships between these adherence measures and clinically relevant end points and/or cost outcomes to determine their predictive utility. Alternative methods of reporting adherence may have greater clinical significance than traditional measures.

Keywords: abatacept; adherence measures; infliximab; infusible biologics; maintenance therapy; rheumatoid arthritis

References

  1. Arthritis Res Ther. 2009;11(1):R26 - PubMed
  2. Med Care. 2002 Sep;40(9):794-811 - PubMed
  3. Ann Rheum Dis. 2015 Feb;74(2):354-60 - PubMed
  4. Value Health. 2007 Jan-Feb;10(1):3-12 - PubMed
  5. Adv Ther. 2009 Oct;26(10):936-46 - PubMed
  6. Am Health Drug Benefits. 2015 Dec;8(9):494-505 - PubMed
  7. Arthritis Rheum. 2005 Dec 15;53(6):872-8 - PubMed
  8. Value Health. 2008 Jan-Feb;11(1):44-7 - PubMed
  9. Adv Ther. 2011 Aug;28(8):671-83 - PubMed
  10. JAMA. 2009 Mar 25;301(12):1260-72 - PubMed
  11. Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S72-84 - PubMed
  12. Arthritis Rheum. 2011 Mar;63(3):633-9 - PubMed
  13. Am J Manag Care. 2009 Jun 01;15(6):e22-33 - PubMed
  14. Patient Prefer Adherence. 2013 Jun 12;7:509-16 - PubMed
  15. Expert Rev Clin Immunol. 2012 May;8(4):337-51 - PubMed
  16. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39 - PubMed
  17. Health Aff (Millwood). 2011 Jan;30(1):91-9 - PubMed
  18. Med Care. 2005 Jun;43(6):521-30 - PubMed
  19. Arthritis Rheum. 2003 Oct;48(10):2750-62 - PubMed
  20. Rheumatology (Oxford). 2007 Mar;46(3):529-32 - PubMed
  21. Int J Clin Rheumtol. 2010 Jun 1;5(3):313-326 - PubMed
  22. Joint Bone Spine. 2005 Jul;72(4):309-12 - PubMed
  23. Exp Clin Transplant. 2003 Jun;1(1):39-47 - PubMed
  24. Arthritis Res Ther. 2009;11 Suppl 1:S1 - PubMed
  25. J Manag Care Pharm. 2012 Sep;18(7):527-39 - PubMed
  26. Arthritis Rheum. 2008 Jun 15;59(6):762-84 - PubMed
  27. Adv Ther. 2005 Jul-Aug;22(4):313-56 - PubMed
  28. J Chronic Dis. 1987;40(5):373-83 - PubMed
  29. Patient Prefer Adherence. 2012;6:417-26 - PubMed
  30. Arthritis Rheum. 1999 Jun;42(6):1209-18 - PubMed
  31. Am J Med Qual. 2006 Jul-Aug;21(4):269-75 - PubMed
  32. Adv Ther. 2015 Apr;32(4):341-55 - PubMed
  33. Orthop Nurs. 2010 Jul-Aug;29(4):260-75 - PubMed
  34. J Manag Care Pharm. 2006 Sep;12(7):555-69 - PubMed
  35. Am J Med Sci. 2010 Oct;340(4):282-90 - PubMed
  36. Z Rheumatol. 2011 Apr;70(3):232-4, 236-8 - PubMed
  37. Expert Opin Biol Ther. 2010 Sep;10(9):1367-78 - PubMed
  38. Curr Rheumatol Rep. 2014 Nov;16(11):460 - PubMed

Publication Types